Genmab — Marts 2023
-
Godmorgen
-
Capital Increase in Genmab as a Result of Employee Warrant Exercise https://www.proinvestor.com/investornyt/947962/capital-increase-in-genmab-as-a-result-of-employee-warrant-exercise
-
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications https://www.sciencedirect.com/science/article/pii/S152573042200256X
-
Merck’s Keytruda fails more prostate and lung cancer PhIII trials https://endpts.com/mercks-keytruda-fails-more-prostate-and-lung-cancer-phiii-trials/
-
Mon ikke gaveboden i Genmab er ved at lukke for denne omgang, så vi kan blive fri for de daglige meldinger om increase m.m.
-
Man kunne ønske, at det vil give et lille puf på kursen
-
another attempt at Dara in AML - Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM) (DARALAM) https://clinicaltrials.gov/ct2/show/NCT05749276?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody+OR+hexabody+OR+Teclistamab+OR+Amivantamab+OR+Talquetamab+OR+Epcoritamab+OR+DuoHe
-
Godmorgen
(teprotumumab-trbw) Net Sales Q4 '22 of $493.5 Million --
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind